JP2023535074A5 - - Google Patents
Info
- Publication number
- JP2023535074A5 JP2023535074A5 JP2023504636A JP2023504636A JP2023535074A5 JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5 JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023504636 A JP2023504636 A JP 2023504636A JP 2023535074 A5 JP2023535074 A5 JP 2023535074A5
- Authority
- JP
- Japan
- Prior art keywords
- complex according
- disease
- antibody
- myopathy
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063055785P | 2020-07-23 | 2020-07-23 | |
| US63/055,785 | 2020-07-23 | ||
| US202063061842P | 2020-08-06 | 2020-08-06 | |
| US63/061,842 | 2020-08-06 | ||
| US202063069078P | 2020-08-23 | 2020-08-23 | |
| US63/069,078 | 2020-08-23 | ||
| US202163143831P | 2021-01-30 | 2021-01-30 | |
| US63/143,831 | 2021-01-30 | ||
| US202163181450P | 2021-04-29 | 2021-04-29 | |
| US63/181,450 | 2021-04-29 | ||
| PCT/US2021/041003 WO2022020108A1 (en) | 2020-07-23 | 2021-07-09 | Muscle-targeting complexes and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535074A JP2023535074A (ja) | 2023-08-15 |
| JP2023535074A5 true JP2023535074A5 (https=) | 2024-07-18 |
| JP7828947B2 JP7828947B2 (ja) | 2026-03-12 |
Family
ID=79728348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504636A Active JP7828947B2 (ja) | 2020-07-23 | 2021-07-09 | 筋標的化複合体およびそれらの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230287108A1 (https=) |
| EP (1) | EP4185329A4 (https=) |
| JP (1) | JP7828947B2 (https=) |
| CN (2) | CN116194470B (https=) |
| AU (1) | AU2021313058A1 (https=) |
| CA (1) | CA3186755A1 (https=) |
| WO (1) | WO2022020108A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20230023612A (ko) | 2020-04-02 | 2023-02-17 | 마이레큘, 인크. | 조작된 올리고뉴클레오티드를 사용한 표적화된 억제 |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| WO2022270585A1 (ja) | 2021-06-23 | 2022-12-29 | 日本新薬株式会社 | アンチセンスオリゴマーの組み合わせ |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US20240382513A1 (en) * | 2021-07-09 | 2024-11-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| WO2023168427A1 (en) * | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| AU2024299328A1 (en) | 2023-07-21 | 2026-01-22 | Marrow Therapeutics, Inc. | Hematopoietic cell targeting conjugates and related methods |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
| WO2025215092A1 (en) * | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8734799B2 (en) * | 2010-04-13 | 2014-05-27 | The Regents Of The University Of California | Unconjugated anti-TfR antibodies and compositions thereof for the treatment of cancer |
| BR112013014527A2 (pt) * | 2010-12-20 | 2017-03-07 | Genentech Inc | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, uso do imunoconjugado, método para tratamento de um indivíduo que tem um câncer positivo para mesotelina, para inibição de proliferação de uma célula positiva para mesotelina, para detecção de mesotelina humana em uma amostra biológica e para detectar um câncer positivo para mesotelina |
| EA039366B1 (ru) * | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| FR3049951A1 (fr) * | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
| BR112019012328A2 (pt) | 2016-12-15 | 2019-11-19 | Abbvie Biotherapeutics Inc | anticorpos anti-ox40 e seus usos |
| PL3691692T3 (pl) | 2017-10-14 | 2021-07-19 | Abbvie Inc. | Koniugaty lek-aktywowalne przeciwciało anty-cd71 i sposoby ich wykorzystania |
| TWI869346B (zh) * | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2020028842A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
| CA3108282A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| IL280536B2 (en) | 2018-08-02 | 2024-12-01 | Dyne Therapeutics Inc | Complexes targeting transferrin receptor and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP2023535078A (ja) * | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス，インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
| KR20230041760A (ko) * | 2020-07-23 | 2023-03-24 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
| EP4185320A4 (en) * | 2020-07-23 | 2025-10-08 | Dyne Therapeutics Inc | MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY |
| MX2023000984A (es) * | 2020-07-23 | 2023-05-03 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de distrofinopatias. |
| KR20230046297A (ko) * | 2020-07-23 | 2023-04-05 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
-
2021
- 2021-07-09 CN CN202180064691.XA patent/CN116194470B/zh active Active
- 2021-07-09 JP JP2023504636A patent/JP7828947B2/ja active Active
- 2021-07-09 US US18/017,180 patent/US20230287108A1/en active Pending
- 2021-07-09 EP EP21845571.5A patent/EP4185329A4/en active Pending
- 2021-07-09 AU AU2021313058A patent/AU2021313058A1/en active Pending
- 2021-07-09 WO PCT/US2021/041003 patent/WO2022020108A1/en not_active Ceased
- 2021-07-09 CA CA3186755A patent/CA3186755A1/en active Pending
- 2021-07-09 CN CN202511290690.3A patent/CN121270701A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023535074A5 (https=) | ||
| CN116194470B (zh) | 肌肉靶向复合物及其用途 | |
| JP2023535444A5 (https=) | ||
| CN114025805B (zh) | 制备蛋白质-寡核苷酸复合物的方法 | |
| JP2023535078A5 (https=) | ||
| JP2023510351A5 (https=) | ||
| Ivanova et al. | Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle | |
| CN116368150A (zh) | 肌肉靶向复合物及其用于治疗肌养蛋白病的用途 | |
| JP2021533200A5 (https=) | ||
| JP2023512442A5 (https=) | ||
| CN116348138A (zh) | 抗转铁蛋白受体（tfr）抗体及其用途 | |
| JP2021532832A5 (https=) | ||
| JP2024525614A5 (https=) | ||
| JP2021533199A5 (https=) | ||
| CN112930197A (zh) | 肌肉靶向复合物及其用途 | |
| CN112912399A (zh) | 肌肉靶向复合物及其用于治疗蓬佩病的用途 | |
| JP2021533197A5 (https=) | ||
| CN112955154A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 | |
| JP2023512441A5 (https=) | ||
| JP2008527993A (ja) | 特異性及び送達の改善のためのｓｉＲＮＡ分子、ｓｈＲＮＡ分子又はアンチセンス分子及び機能的実体を含む複合体 | |
| CN116438304A (zh) | 肌肉靶向复合物及其用于治疗强直性肌营养不良的用途 | |
| US20040198640A1 (en) | Stabilized polynucleotides for use in RNA interference | |
| CN113164620A (zh) | 肌肉靶向复合物及其用于治疗进行性骨化性纤维结构不良的用途 | |
| TW200930382A (en) | LNA antagonists targeting the androgen receptor | |
| US12084662B2 (en) | Compositions and methods for modulating PNPLA3 expression |